143 related articles for article (PubMed ID: 36049756)
1. Influence of Sodium-Glucose Cotransporter-2 Inhibitors on Plasma Adiponectin in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.
Wang Y; Xia N
Horm Metab Res; 2022 Dec; 54(12):833-844. PubMed ID: 36049756
[TBL] [Abstract][Full Text] [Related]
2. Effects of sodium-glucose cotransporter 2 inhibitors on serum uric acid in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis.
Hu X; Yang Y; Hu X; Jia X; Liu H; Wei M; Lyu Z
Diabetes Obes Metab; 2022 Feb; 24(2):228-238. PubMed ID: 34617381
[TBL] [Abstract][Full Text] [Related]
3. Systematic Review and Meta-Analysis of Randomized Controlled Trials on the Effect of SGLT2 Inhibitor on Blood Leptin and Adiponectin Level in Patients with Type 2 Diabetes.
Wu P; Wen W; Li J; Xu J; Zhao M; Chen H; Sun J
Horm Metab Res; 2019 Aug; 51(8):487-494. PubMed ID: 31408894
[TBL] [Abstract][Full Text] [Related]
4. Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials.
Li CX; Liu LY; Zhang CX; Geng XH; Gu SM; Wang YQ; Liu H; Xie Q; Liang S
Front Endocrinol (Lausanne); 2023; 14():1238399. PubMed ID: 37701900
[TBL] [Abstract][Full Text] [Related]
5. Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
Pan R; Zhang Y; Wang R; Xu Y; Ji H; Zhao Y
PLoS One; 2022; 17(12):e0279889. PubMed ID: 36584211
[TBL] [Abstract][Full Text] [Related]
6. Effects of SGLT-2 inhibitors on adipose tissue distribution in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
Wang X; Wu N; Sun C; Jin D; Lu H
Diabetol Metab Syndr; 2023 May; 15(1):113. PubMed ID: 37254186
[TBL] [Abstract][Full Text] [Related]
7. Sodium-glucose cotransporter inhibitors as add-on therapy in addition to insulin for type 1 diabetes mellitus: A meta-analysis of randomized controlled trials.
Zou H; Liu L; Guo J; Wang H; Liu S; Xing Y; Deng C; Xiao Y; Zhou Z
J Diabetes Investig; 2021 Apr; 12(4):546-556. PubMed ID: 33245620
[TBL] [Abstract][Full Text] [Related]
8. Effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on serum uric acid levels in patients with chronic kidney disease: a systematic review and network meta-analysis.
Zhang L; Zhang F; Bai Y; Huang L; Zhong Y; Zhang X
BMJ Open Diabetes Res Care; 2024 Jan; 12(1):. PubMed ID: 38238025
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of combination therapy with sodium-glucose cotransporter 2 inhibitors and renin-angiotensin system blockers in patients with type 2 diabetes: a systematic review and meta-analysis.
Tian B; Deng Y; Cai Y; Han M; Xu G
Nephrol Dial Transplant; 2022 Mar; 37(4):720-729. PubMed ID: 33605424
[TBL] [Abstract][Full Text] [Related]
10. Effects of sodium-glucose cotransporter 2 inhibitors on bone metabolism in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
Wang J; Li X; Li Y; Lei C
BMC Endocr Disord; 2024 Apr; 24(1):52. PubMed ID: 38658986
[TBL] [Abstract][Full Text] [Related]
11. The effect of sodium-glucose cotransporter-2 inhibitors on inflammatory biomarkers: A meta-analysis of randomized controlled trials.
Buttice L; Ghani M; Suthakar J; Gnanalingham S; Carande E; Kennedy BWC; Pitcher A; Gamble JHP; Ahmad M; Lewis A; Jüni P; Rider OJ; Stephens JW; Bray JJH
Diabetes Obes Metab; 2024 Jul; 26(7):2706-2721. PubMed ID: 38602398
[TBL] [Abstract][Full Text] [Related]
12. The different hypoglycemic effects between East Asian and non-Asian type 2 diabetes patients when treated with SGLT-2 inhibitors as an add-on treatment for metformin: a systematic review and meta-analysis of randomized controlled trials.
Li X; Zhang Q; Zhou X; Guo S; Jiang S; Zhang Y; Zhang R; Dong J; Liao L
Aging (Albany NY); 2021 May; 13(9):12748-12765. PubMed ID: 33973870
[TBL] [Abstract][Full Text] [Related]
13. SGLT-2 Inhibitors and DPP-4 Inhibitors as Second-Line Drugs in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Clinical Trials.
Wang K; Zhang Y; Zhao C; Jiang M
Horm Metab Res; 2018 Oct; 50(10):768-777. PubMed ID: 30261527
[TBL] [Abstract][Full Text] [Related]
14. SGLT inhibitors on weight and body mass: A meta-analysis of 116 randomized-controlled trials.
Cheong AJY; Teo YN; Teo YH; Syn NL; Ong HT; Ting AZH; Chia AZQ; Chong EY; Chan MY; Lee CH; Lim AYL; Kong WKF; Wong RCC; Chai P; Sia CH
Obesity (Silver Spring); 2022 Jan; 30(1):117-128. PubMed ID: 34932882
[TBL] [Abstract][Full Text] [Related]
15. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
[TBL] [Abstract][Full Text] [Related]
16. Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Zhang A; Luo X; Meng H; Kang J; Qin G; Chen Y; Zhang X
Front Endocrinol (Lausanne); 2020; 11():604250. PubMed ID: 33519713
[TBL] [Abstract][Full Text] [Related]
17. Effect of sodium-glucose cotransporter 2 inhibitors on insulin resistance; a systematic review and meta-analysis.
Fakhrolmobasheri M; Abhari AP; Manshaee B; Heidarpour M; Shafie D; Mohammadbeigi E; Mozafari AM; Mazaheri-Tehrani S
Acta Diabetol; 2023 Feb; 60(2):191-202. PubMed ID: 36264350
[TBL] [Abstract][Full Text] [Related]
18. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials.
Teo YN; Ting AZH; Teo YH; Chong EY; Tan JTA; Syn NL; Chia AZQ; Ong HT; Cheong AJY; Li TY; Poh KK; Yeo TC; Chan MY; Wong RCC; Chai P; Sia CH
Am J Cardiovasc Drugs; 2022 May; 22(3):299-323. PubMed ID: 35316484
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
Kosiborod M; Lam CSP; Kohsaka S; Kim DJ; Karasik A; Shaw J; Tangri N; Goh SY; Thuresson M; Chen H; Surmont F; Hammar N; Fenici P;
J Am Coll Cardiol; 2018 Jun; 71(23):2628-2639. PubMed ID: 29540325
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
Feng M; Lv H; Xu X; Wang J; Lyu W; Fu S
Medicine (Baltimore); 2019 Jul; 98(30):e16575. PubMed ID: 31348290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
